Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
AIDS
MCID: ACQ007
MIFTS: 60

Acquired Immunodeficiency Syndrome (AIDS)

Categories: Blood diseases, Cancer diseases, Immune diseases, Infectious diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Acquired Immunodeficiency Syndrome

About this section

MalaCards integrated aliases for Acquired Immunodeficiency Syndrome:

Name: Acquired Immunodeficiency Syndrome 12 43 15 71
Acquired Immune Deficiency Syndrome 12 3 15
Aids 12 47
Acquired Immune Deficiency 12
Acquired Immunodeficiency 58

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32
Orphanet: 58  
Rare immunological diseases


External Ids:

Disease Ontology 12 DOID:635
MeSH 43 D000163
NCIt 49 C2851
SNOMED-CT 67 62479008
ICD10 32 B20
UMLS via Orphanet 72 C0001175
Orphanet 58 ORPHA310050
UMLS 71 C0001175
Sources

Summaries for Acquired Immunodeficiency Syndrome

About this section
CDC : 3 HIV is a virus spread through certain body fluids that attacks the body's immune system, specifically the CD4 cells, often called T cells. Over time, HIV can destroy so many of these cells that the body can't fight off infections and disease. These special cells help the immune system fight off infections. Untreated, HIV reduces the number of CD4 cells (T cells) in the body. This damage to the immune system makes it harder and harder for the body to fight off infections and some other diseases. Opportunistic infections or cancers take advantage of a very weak immune system and signal that the person has AIDS. Learn more about the stages of HIV and how to know whether you have HIV.

MalaCards based summary : Acquired Immunodeficiency Syndrome, also known as acquired immune deficiency syndrome, is related to human immunodeficiency virus type 1 and granulomatosis with polyangiitis. An important gene associated with Acquired Immunodeficiency Syndrome is HCP5 (HLA Complex P5), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Mycophenolic acid and Oseltamivir have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and brain, and related phenotypes are cellular and endocrine/exocrine gland

Disease Ontology : 12 A Human immunodeficiency virus infectious disease that results in reduction in the numbers of CD4-bearing helper T cells below 200 per ��L of blood or 14% of all lymphocytes thereby rendering the subject highly vulnerable to life-threatening infections and cancers, has material basis in Human immunodeficiency virus 1 or has material basis in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. Opportunistic infections are common in people with AIDS.

Sources

Related Diseases for Acquired Immunodeficiency Syndrome

About this section

Diseases related to Acquired Immunodeficiency Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3028)
# Related Disease Score Top Affiliating Genes
1 human immunodeficiency virus type 1 33.8 TNF ITIH4 IL6 IL2 IL10 IFNG
2 granulomatosis with polyangiitis 32.9 TNF CD40LG CD4 CCR5
3 immune deficiency disease 32.7 TNF ITIH4 IL6 IL2 IL10 IFNG
4 kaposi sarcoma 32.7 MYC IL6 CSF2 CCR5
5 neuroretinitis 32.4 IFNG CD40LG CD4
6 chronic mucocutaneous candidiasis 32.4 TNF IL6 IL10 IFNG CSF2 CD4
7 toxoplasmosis 32.2 TNF IL6 IL10 IFNG CD40LG CCR5
8 cryptococcosis 32.2 TNF IL10 IFNG CSF2 CD4
9 cytomegalovirus infection 32.1 TNF IL6 HLA-B B2M
10 cryptococcal meningitis 32.1 IFNG CSF2 CD4
11 lymphoma 32.1 MYC IL6 IL2 CD40LG CD38 CCR5
12 cytomegalovirus retinitis 32.1 TNF IL10 IFNG HLA-B CSF2 CD4
13 histoplasmosis 32.1 TNF IFNG HLA-B CD40LG CD4
14 encephalitis 32.0 TNF ITIH4 IL6 IL10 CD40LG CCR5
15 pneumocystosis 32.0 TNF IL6 CD40LG CD4 CCR5 ALB
16 progressive multifocal leukoencephalopathy 32.0 TNF IL2 CD40LG CD4
17 candidiasis 31.9 TNF IL6 IL2 IL10 IFNG CSF2
18 diarrhea 31.9 TNF IL6 IL2 IL10 IFNG CD40LG
19 central nervous system lymphoma 31.9 MYC IL6 IL2 IL10
20 retinitis pigmentosa 31.9 TNF NEAT1 MYC IL6 IL2 IL10
21 respiratory failure 31.8 TNF IL6 IL10 CD4 ALB
22 lymphopenia 31.8 IL6 IL2 IL10 IFNG
23 vasculitis 31.8 TNF IL6 HLA-B CD40LG
24 esophagitis 31.8 TNF IL6 IL10
25 syphilis 31.7 CD40LG CD4 CCR5 B2M ALB
26 aspergillosis 31.7 TNF IL6 IL10 IFNG CSF2
27 aids dementia complex 31.7 TNF ITIH4 B2M
28 chickenpox 31.6 TNF IL6 IL2 IL10 IFNG CD40LG
29 pancytopenia 31.6 IL6 IFNG CSF2 CD40LG CD4
30 visceral leishmaniasis 31.6 TNF IL2 IL10 IFNG ALB
31 pericardial effusion 31.6 IL6 CD40LG CD4 ALB
32 pulmonary tuberculosis 31.6 TNF IL6 IL2 IL10 IFNG ALB
33 colitis 31.6 TNF IL6 IL2 IL10 IFNG
34 exanthem 31.6 TNF IL6 IL2 IL10 CSF2 CD40LG
35 bacterial infectious disease 31.6 TNF ITIH4 IL6 IL10 IFNG CSF2
36 mycobacterium tuberculosis 1 31.5 TNF IL10 IFNG CD4
37 pneumonia 31.5 TNF IL6 IL2 IL10 IFNG CSF2
38 endocarditis 31.5 TNF IL6 IL10 IFNG ALB
39 pericarditis 31.5 TNF IL6 IFNG CD40LG ALB
40 extrapulmonary tuberculosis 31.5 TNF IL10 IFNG CD4 ALB
41 meningitis 31.5 TNF IL6 IL2 IL10 IFNG HLA-B
42 uveitis 31.5 TNF IL6 IL2 IL10 IFNG HLA-B
43 myelitis 31.5 TNF IL6 IL10 CD40LG
44 lymphadenitis 31.5 TNF IL10 IFNG CD4
45 purpura 31.5 TNF IL6 IL10 CD40LG
46 bacterial pneumonia 31.5 TNF IL6 IL10 CD40LG CD4 ALB
47 strongyloidiasis 31.5 IFNG CD40LG CD4
48 myocarditis 31.5 TNF IL6 IL2 IL10 IFNG HLA-B
49 keratitis, hereditary 31.5 TNF IL6 IL10 CD4
50 osteomyelitis 31.4 TNF IL6 IL10 IFNG

Graphical network of the top 20 diseases related to Acquired Immunodeficiency Syndrome:



Diseases related to Acquired Immunodeficiency Syndrome
Sources

Symptoms & Phenotypes for Acquired Immunodeficiency Syndrome

About this section

MGI Mouse Phenotypes related to Acquired Immunodeficiency Syndrome:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.32 ALB B2M CCR5 CD38 CD4 CD40LG
2 endocrine/exocrine gland MP:0005379 10.25 ALB B2M CD38 CD4 CD40LG CSF2
3 cardiovascular system MP:0005385 10.24 ALB B2M CCR5 CD40LG CSF2 IFNG
4 hematopoietic system MP:0005397 10.18 B2M CCR5 CD38 CD4 CD40LG CSF2
5 homeostasis/metabolism MP:0005376 10.18 ALB B2M CCR5 CD38 CD4 CD40LG
6 digestive/alimentary MP:0005381 10.16 ALB B2M CCR5 CD4 IFNG IL10
7 immune system MP:0005387 10.13 ALB B2M CCR5 CD38 CD4 CD40LG
8 integument MP:0010771 9.91 B2M CD4 CD40LG CSF2 IFNG IL10
9 liver/biliary system MP:0005370 9.85 ALB B2M CCR5 IFNG IL10 IL2
10 neoplasm MP:0002006 9.7 ALB B2M CCR5 CSF2 IFNG IL10
11 reproductive system MP:0005389 9.36 B2M CCR5 CD40LG CSF2 IFNG IL10
Sources

Drugs & Therapeutics for Acquired Immunodeficiency Syndrome

About this section

Drugs for Acquired Immunodeficiency Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 995)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4 24280-93-1 446541
2
Oseltamivir Approved Phase 4 196618-13-0, 204255-11-8 65028
3
Sodium sulfate Approved, Vet_approved Phase 4 7757-82-6
4
Sodium Tetradecyl Sulfate Approved, Investigational Phase 4 139-88-8, 1191-50-0 14492 5248
5
Didanosine Approved Phase 4 69655-05-6 50599
6
Fosamprenavir Approved Phase 4 226700-79-4 131536
7
Indinavir Approved Phase 4 150378-17-9 5362440
8
leucovorin Approved Phase 4 58-05-9 6006 143
9
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
10
Sulfamethoxazole Approved Phase 4 723-46-6 5329
11
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
12
Sulfadiazine Approved, Investigational, Vet_approved Phase 4 68-35-9 5215
13
Megestrol acetate Approved, Investigational, Vet_approved Phase 4 595-33-5 11683
14
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
15
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
16
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
18
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
19
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
20
Acetaminophen Approved Phase 4 103-90-2 1983
21
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
22
Ferrous fumarate Approved Phase 4 141-01-5
23
Ledipasvir Approved Phase 4 1256388-51-8 67505836
24
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
25
Enfuvirtide Approved, Investigational Phase 4 159519-65-0 16130199
26
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
27
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
28
Copper Approved, Investigational Phase 4 7440-50-8 27099
29
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
30
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
31
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
32
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
33
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
34
Desipramine Approved, Investigational Phase 4 50-47-5 2995
35
Lumefantrine Approved Phase 4 82186-77-4 6437380
36
Artemether Approved Phase 4 71963-77-4 119380 68911
37
Oxandrolone Approved, Investigational Phase 4 53-39-4 5878
38
Hexetidine Approved, Investigational Phase 4 141-94-6
39
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
40
Promethazine Approved, Investigational Phase 4 60-87-7 4927
41
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
42
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
43
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
44
Temazepam Approved, Investigational Phase 4 846-50-4 5391
45
Doxepin Approved, Investigational Phase 4 1668-19-5 667477 667468
46
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
47
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
48
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
49
Pancrelipase Approved, Investigational Phase 4 53608-75-6
50
Calcium acetate Approved, Investigational Phase 4 62-54-4

Interventional clinical trials:

(show top 50) (show all 4808)
# Name Status NCT ID Phase Drugs
1 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
2 Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
3 Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
4 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
5 Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach Unknown status NCT01875952 Phase 4 Isoniazid
6 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
7 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4 Truvada (tenofovir/emitricitabine);Kaletra (lopinavir/ritonavir)
8 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
9 The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial Unknown status NCT02401828 Phase 4 Dolutegravir
10 Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring Unknown status NCT00836212 Phase 4 Reducing dose of Lopinavir;Reducing dose of efavirenz
11 Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B Unknown status NCT03120494 Phase 4 Emtricitabine and Tenofovir
12 Hepatic Safety of Raltegravir-based and Efavirenz-based Antiretroviral Regimens in Antiretroviral-Naïve HIV-infected Subjects Co-Infected With Hepatitis C Unknown status NCT01147107 Phase 4 Raltegravir;Efavirenz
13 The Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha) in Patients With Conductive or Mixed Hearing Loss, or Unilateral Deafness Unknown status NCT01264510 Phase 4
14 An Open Pilot Study to Evaluate the Efficacy and Safety, Tolerability of Raltegravir（RAL）in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
15 Curing HCV in Incarcerated Patients Unknown status NCT03018353 Phase 4 Patients receiving Sof/Vel (Epclusa) and Navigation services
16 Treating HIV-infected Elite Controllers as a Model of HIV Remission Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
17 Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous Malformations Unknown status NCT01347294 Phase 4 Bleomycin;Fibrovein;Bleomycin + Fibrovein
18 Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults Unknown status NCT01782950 Phase 4 Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
19 Clinical and Microbiological Effects of an Essential Oils Solution Used as an Adjunct to Daily Oral Hygiene Practices in Chronic Periodontitis Patients in Supportive Care Unknown status NCT01195493 Phase 4
20 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
21 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled，Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
22 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
23 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
24 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
25 Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort Completed NCT00618176 Phase 4 Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP);Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP);Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)
26 Long-term Safety of Subjects Continuing Dolutegravir After Participation in Clinical Studies of Dolutegravir in Russian Federation Completed NCT03314064 Phase 4 Dolutegravir 50 mg
27 Interferon Alfa Sensitivity in HIV/HCV Coinfected Persons Before and After Antiretroviral Therapy Completed NCT01285050 Phase 4 Antiretroviral therapy (ART);raltegravir;Emtricitabine and tenofovir disoproxil fumarate
28 An Open-Label Randomized Pharmacokinetic/Pharmacodynamic Study of Mycobutin (Rifabutin) or Rifabutin in Combination With Myambutol (Ethambutol) for Prophylaxis of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts <= 100 Cells/mm3 Completed NCT00002343 Phase 4 Ethambutol hydrochloride;Rifabutin
29 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
30 A Randomised Comparator Study to Assess the Relative Efficacy of Genotypic Versus Virtual Phenotypic Resistance Tests in Treatment Experienced Patients With HIV Infection for Whom a Change in Therapy is Indicated Completed NCT00262717 Phase 4
31 An Open-label Phase III Study to Provide Access to Fosamprenavir and to Assess the Long Term Safety and Tolerability of Fosamprenavir Containing Regimens in HIV Infected Patients With Limited Treatment Options Completed NCT00240552 Phase 4 fosamprenavir;Telzir®
32 An Open-label Single Oral Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-0518 1200 mg (600 mg Tablet × 2) in Healthy Japanese Male Participants Completed NCT03667547 Phase 4 Raltegravir
33 Phase IV, Non Randomized Study in ARV Experienced Patients Under Switch Therapy With Kaletra Completed NCT00648999 Phase 4 lopinavir/ritonavir
34 Gradual Initiation of Trimethoprim/Sulfamethoxazole as Primary Pneumocystis Carinii Pneumonia Prophylaxis Completed NCT00000816 Phase 4 Sulfamethoxazole-Trimethoprim
35 Project STRIDE2 - Seek/Test/Retain: PLWHA and Opioid Users in Washington, DC Completed NCT03583138 Phase 4 buprenorphine
36 Defining the Rectal Mucosa in Men Who Have Sex With Men at Risk of HIV Infection Completed NCT02401230 Phase 4 Truvada
37 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo
38 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
39 Pre-Exposure Prophylaxis (PrEP) Initiation and Adherence Among Black Men Who Have Sex With Men (BMSM) in Three U.S. Cities Completed NCT01808352 Phase 4 FTC/TDF
40 Continuous Versus Cyclic Use of Combined Oral Contraceptive Pills Completed NCT00570440 Phase 4 Oral contraceptives--ethinyl estradiol, levonorgestrel
41 An Open-Label Study of Nevirapine Plus Combivir® (ZDV+3TC) Treatment in Women Who Have Previously Received a Nevirapine Regimen for the Prevention of Mother to Child Transmission (pMTCT) of HIV-1. Completed NCT00144157 Phase 4 Nevirapine;Zidovudine;3TC
42 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4 fluconazole
43 Intranasal Mupirocin to Eliminate Carriage of Staphylococcus Aureus in HIV Infection Completed NCT00801879 Phase 4 Mupirocin calcium ointment, 2%;Placebo ointment
44 Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study) Completed NCT00263458 Phase 4
45 Randomized, Open-Label 2x2 Factorial Study to Compare the Safety and Efficacy of Different Combination Antiretroviral Therapy Regimens in Treatment Naive Patients With Advanced HIV Disease and/or CD4+ Cell Counts Less Than 200 Cells/MicroL Completed NCT00342355 Phase 4 Zidovudine;Stavudine;Didanosine;Lamivudine;Efavirenz;Lopinavir/Ritonavir
46 Prospective Epidemiological Study of the Prevalence of HLAB*5701 in HIV-1 Infected Patients Completed NCT00441688 Phase 4 GI265235
47 Phase IV Study on the Safety and Efficacy of Megace Oral Suspension in HIV-Positive Females Completed NCT00002345 Phase 4 Megestrol acetate
48 Safety and Immunogenicity of Cervarix™ in Human Immunodeficiency Virus Infected Females Completed NCT01031069 Phase 4
49 A Pharmacokinetic Study to Evaluate the Interaction Between Nevirapine (Viramune®) and Methadone in HIV-1 Infected, Opioid-dependent Adults on Stable Methadone Maintenance Therapy Completed NCT00273988 Phase 4 nevirapine
50 A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa. Completed NCT02348177 Phase 4 lopinavir with ritonavir in 1:1 ratio;Lopinavir/ritonavir 4:1

Search NIH Clinical Center for Acquired Immunodeficiency Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


abacavir
abacavir sulfate
Amprenavir
Delavirdine
Delavirdine Mesylate
Didanosine
efavirenz
enfuvirtide
Immunoglobulins, Intravenous
Indinavir
Indinavir Sulfate
Lamivudine
lopinavir
Nelfinavir
Nelfinavir Mesylate
Nevirapine
Ritonavir
Saquinavir
saquinavir mesylate
Stavudine
Tenofovir
tenofovir alafenamide fumarate
Tenofovir disoproxil fumarate
Zalcitabine
Zidovudine

Cochrane evidence based reviews: acquired immunodeficiency syndrome

Sources

Genetic Tests for Acquired Immunodeficiency Syndrome

About this section
Sources

Anatomical Context for Acquired Immunodeficiency Syndrome

About this section

MalaCards organs/tissues related to Acquired Immunodeficiency Syndrome:

40
Testes, T Cells, Brain, Bone, Breast, Lung, Liver
Sources

Publications for Acquired Immunodeficiency Syndrome

About this section

Articles related to Acquired Immunodeficiency Syndrome:

(show top 50) (show all 20813)
# Title Authors PMID Year
1
Achievement of long-term remission of disseminated histoplasmosis in an AIDS patient. 61
31908909 2020
2
A correlation analysis of HHV infection and its predictive factors in an HIV-seropositive population in Yunnan, China. 61
31621089 2020
3
Effects of CD4 cell count and antiretroviral therapy on mucocutaneous manifestations among HIV/AIDS patients in Yunnan, China. 61
31846069 2020
4
SLC11A1 (rs3731865) polymorphism and susceptibility to visceral leishmaniasis in HIV-coinfected patients from Northeastern Brazil. 61
31907667 2020
5
Estimating HIV Management and Comorbidity Costs Among Aging HIV Patients in the United States: A Systematic Review. 61
32011956 2020
6
Disease-Specific Mortality and Prevalence Trends in Korea, 2002-2015. 61
31997615 2020
7
Perceived quality of HIV care and client satisfaction across different service providers in Ukraine. 61
31270547 2020
8
A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy. 61
31352645 2020
9
An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. 61
32036729 2020
10
Can we use structural knowledge to design a protective vaccine against HIV-1? 61
31721469 2020
11
Incidence and Trends in Immune Reconstitution Inflammatory Syndrome Associated With Histoplasma capsulatum Among People Living With Human Immunodeficiency Virus: A 20-Year Case Series and Literature Review. 61
30921453 2020
12
Effect of anesthetic method on incidence of delirium after total hip replacement arthroplasty in South Korea: a population-based study using National Health Insurance claims data. 61
31378056 2020
13
Perioperative Antiretroviral Regimen for HIV/AIDS Patients Who Underwent Abdominal Surgery. 61
32020326 2020
14
Giving Back Is Receiving: The Role of Generativity in Successful Aging Among HIV-Positive Older Adults. 61
30289022 2020
15
Impact of community pharmacist-led interventions in chronic disease management on clinical, utilization, and economic outcomes: An umbrella review. 61
31959565 2020
16
Strategies to facilitate safe sexual practices in adolescents through integrated health systems in selected districts of Zimbabwe: a mixed method study protocol. 61
32005263 2020
17
Significance of Decreasing Rate of HIV and HBV Co-infection in a Nationwide Korean HIV/AIDS Cohort. 61
31950774 2020
18
Circulating (1→3)-β-D-glucan Is Associated With Immune Activation During Human Immunodeficiency Virus Infection. 61
30877304 2020
19
Follicular Helper T Cells Are Major Human Immunodeficiency Virus-2 Reservoirs and Support Productive Infection. 61
31504642 2020
20
Prevalence and characteristics of occult hepatitis B virus infection in Japanese human immunodeficiency virus-infected patients. 61
31279522 2020
21
Does Endogenous Endophthalmitis Need a More Aggressive Treatment? 61
31951759 2020
22
Neural Tube Defects in Pregnancies Among Women With Diagnosed HIV Infection - 15 Jurisdictions, 2013-2017. 61
31917782 2020
23
Roles and potential applications of lncRNAs in HIV infection. 61
31945493 2020
24
Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study. 61
30919882 2020
25
The activist health sciences librarian. 61
31897047 2020
26
Antiviral Drug Targets of Single-Stranded RNA Viruses Causing Chronic Human Diseases. 61
31538891 2020
27
Underexpression of endothelial nitric oxide synthase leads to more severe pulmonary complex vascular lesions associated with HIV patients. 61
31996864 2020
28
HIV biosensors for early diagnosis of infection: The intertwine of nanotechnology with sensing strategies. 61
31514868 2020
29
Talaromyces marneffei Outside Endemic Areas in India: an Emerging Infection with Atypical Clinical Presentations and Review of Published Reports from India. 61
31894499 2020
30
Neuro-Ophthalmic Manifestations of HIV Infection. 61
31961200 2020
31
HIV infection confers distinct mechanisms in severe drug eruption: endogenous virus activation with aberrant Th2/Th1 and CD8+ T cells function. 61
31991490 2020
32
Exploring the potency of currently used drugs against HIV-1 protease of subtype D variant by using multiscale simulations. 61
32000612 2020
33
Pulmonary Mycobacterium Spindle Cell Pseudotumor in Patient With Liver Transplant. 61
31902440 2020
34
Risk Factors for Herpes Zoster Infection: A Meta-Analysis. 61
32010734 2020
35
Sensor Sensibility-HIV-1 and the Innate Immune Response. 61
31968566 2020
36
HIV/AIDS-related beliefs among Israeli Arab-Palestinian women. 61
31515884 2020
37
Comparison of Characteristics and Survival between Prospective and Retrospective Korea Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Cohort Studies. 61
31898427 2019
38
Non-traumatic perforation of the jejunum in a human immunodeficiency virus-infected patient receiving combination antiretroviral therapy: A case report. 61
31804330 2019
39
Capturing public interest toward new tools for controlling human immunodeficiency virus (HIV) infection exploiting data from Google Trends. 61
29638172 2019
40
African Multi-Site 2-Year Neuropsychological Study of School-Age Children Perinatally Infected, Exposed, and Unexposed to Human Immunodeficiency Virus. 61
31848582 2019
41
Determinants of first line antiretroviral therapy treatment failure among adult patients on ART at central Ethiopia: un-matched case control study. 61
31795955 2019
42
Characterizing the Latent HIV-1 Reservoir in Patients with Viremia Suppressed on cART: Progress, Challenges, and Opportunities. 61
31889490 2019
43
Can environmental determinants explain Nontuberculous Mycobacteria geographic incidence? 61
31882260 2019
44
Comparison of the prevalence rates of HIV infection between men who have sex with men (MSM) and men in the general population in sub-Saharan Africa: a systematic review and meta-analysis. 61
31801503 2019
45
[Analysis on the transmission characteristics of newly reported human immunodeficiency virus/acquired immunodeficiency syndrome cases based on the molecular transmission network in Huzhou, Zhejiang, 2017]. 61
31795586 2019
46
Pneumocystis jiroveci pneumonia in Taiwan from 2014 to 2017: Clinical manifestations and outcomes between pediatric and adult patients. 61
31164278 2019
47
Genital Kaposi sarcoma in a HIV and syphilis co-infected patient: case presentation. 61
31888512 2019
48
Primary Nasopharyngeal Kaposi Sarcoma as Index Diagnosis of AIDS in a Previously Healthy Man. 61
30039355 2019
49
Associations of Viral Seroreactivity with AIDS-Related Non-Hodgkin Lymphoma. 61
31789046 2019
50
Economic Barriers to Antiretroviral Therapy in Nursing Homes. 61
31829445 2019
Sources

Variations for Acquired Immunodeficiency Syndrome

About this section
Sources

Expression for Acquired Immunodeficiency Syndrome

About this section
Search GEO for disease gene expression data for Acquired Immunodeficiency Syndrome.
Sources

Pathways for Acquired Immunodeficiency Syndrome

About this section

Pathways related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.08 TNF MYC IL6 IL2 IL10 IFNG
2
PEDF Induced Signaling 63
Show member pathways
 13.73 TNF MYC IL6 IL2 IL10 IFNG
3
Akt Signaling 63
Show member pathways
 13.46 TNF IL6 IL2 IL10 CSF2 CD40LG
4
PAK Pathway 63
Show member pathways
 13.35 TNF IL6 IL2 IL10 CSF2 CD40LG
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.32 TNF MYC IL6 IL2 IL10 IFNG
6
Human cytomegalovirus infection 36
Show member pathways
 12.99 TNF MYC IL6 HLA-B CSF2 CD4
7
Measles 36
Show member pathways
 12.89 TNF MYC IL6 IL2 IFNG HLA-B
8
Allograft rejection 1 36
Show member pathways
 12.85 TNF IL6 IL2 IL10 IFNG HLA-B
9
Herpes simplex virus 1 infection 36
12.82 TNF IL6 IFNG HLA-B B2M
10
4-1BB Pathway 63
Show member pathways
 12.71 TNF IFNG CD40LG CD4 CCR5
11
Immune response NFAT in immune response 22
Show member pathways
 12.7 TNF IL2 IL10 IFNG CD40LG CD4
12
Th17 cell differentiation 36
Show member pathways
 12.67 TNF MYC IL6 IL2 IL10 IFNG
13
Immune response IL-23 signaling pathway 22
Show member pathways
 12.64 TNF MYC IL6 IL2 IL10 IFNG
14
NF-kappaB Signaling 4
12.61 TNF IL2 IL10 IFNG CD40LG CD38
15
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.58 TNF IL2 IFNG HLA-B CSF2
16
T cell receptor signaling pathway 36
Show member pathways
 12.45 TNF IL6 IL2 IL10 IFNG CSF2
17
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.4 TNF IL6 IL2 IL10 CCR5
18
Folate Metabolism 1
Show member pathways
 12.4 TNF IL6 IL2 IFNG ALB
19
JAK-STAT signaling pathway (KEGG) 36
Show member pathways
 12.37 MYC IL6 IL2 IL10 IFNG CSF2
20
IL-17 Family Signaling Pathways 64
Show member pathways
 12.36 TNF IL6 IFNG CSF2
21
Toxoplasmosis 36
Show member pathways
 12.33 TNF IL10 IFNG CD40LG CCR5
22
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.33 TNF MYC IL6 IL2 IL10 IFNG
23
Tuberculosis 36
12.28 TNF IL6 IL10 IFNG
24
C-type lectin receptor signaling pathway 36
Show member pathways
 12.26 TNF IL6 IL2 IL10
25
Human T-cell leukemia virus 1 infection 36
12.26 TNF MYC IL6 IL2 HLA-B CSF2
26
Colorectal Cancer Metastasis 63
12.24 TNF MYC IL6 IFNG
27
Microglia Activation During Neuroinflammation: Overview 64
Show member pathways
 12.1 TNF IL6 IFNG CSF2
28
Spinal Cord Injury 1
12.1 TNF MYC IL6 IL2 IFNG
29
Th1 Differentiation Pathway 64
Show member pathways
 12.1 TNF IL6 IL2 IL10 IFNG CD4
30
Yersinia infection 36
12.08 TNF IL6 IL2 IL10
31
IL12-mediated signaling events 1
Show member pathways
 12.07 IL2 IFNG CD4 CCR5 B2M
32
Interleukin-4 and 13 signaling 65
12.05 TNF MYC IL6 IL10
33
Amoebiasis 36
12.01 TNF IL6 IL10 IFNG CSF2
34
Jak-Stat Signaling Pathway (sino) 66
11.99 IL6 IL2 IL10 IFNG CCR5
35
Hematopoietic cell lineage 36
11.99 TNF IL6 CSF2 CD4 CD38
36
Rheumatoid arthritis 36
11.95 TNF IL6 IFNG CSF2
37
Glucocorticoid receptor regulatory network 1
11.88 IL6 IL2 IFNG CSF2
38
Innate Lymphoid Cell Differentiation Pathways 64
11.86 TNF IL2 IL10 IFNG CD4
39
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.82 TNF IL2 IFNG CSF2 CD40LG
40
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.82 TNF IL6 IL2 IL10 IFNG CSF2
41
Salmonella infection (KEGG) 36
11.81 IL6 IFNG CSF2
42
Pertussis 36
11.79 TNF IL6 IL10
43
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.74 TNF IL2 IFNG B2M
44
Microglia Activation During Neuroinflammation: Microglia Polarization 64
11.73 TNF IL6 IL2 IL10 IFNG CSF2
45
Regulation of Telomerase 1
11.72 MYC IL2 IFNG
46
Lung fibrosis 1
11.7 TNF IL6 CSF2
47
B Cell Development Pathways 64
11.67 IL10 CD40LG CD4 CD38
48
Photodynamic therapy-induced AP-1 survival signaling. 1
11.65 TNF IL6 IL2 IFNG
49
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.64 TNF